Aberdeen Group plc Makes New Investment in Palvella Therapeutics, Inc. $PVLA

Aberdeen Group plc purchased a new stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 51,243 shares of the company’s stock, valued at approximately $3,212,000. Aberdeen Group plc owned approximately 0.46% of Palvella Therapeutics at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in PVLA. Archer Investment Corp acquired a new position in shares of Palvella Therapeutics in the third quarter valued at approximately $28,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Palvella Therapeutics during the 2nd quarter worth approximately $37,000. JPMorgan Chase & Co. increased its position in Palvella Therapeutics by 108,066.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after acquiring an additional 3,242 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Palvella Therapeutics in the 2nd quarter valued at approximately $85,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Palvella Therapeutics during the second quarter valued at $104,000. 40.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

PVLA has been the topic of several analyst reports. Canaccord Genuity Group boosted their price objective on shares of Palvella Therapeutics from $148.00 to $204.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. HC Wainwright set a $200.00 target price on Palvella Therapeutics and gave the stock a “buy” rating in a report on Monday, December 15th. Chardan Capital upped their price target on Palvella Therapeutics from $110.00 to $174.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Stifel Nicolaus increased their price target on Palvella Therapeutics from $87.00 to $145.00 and gave the company a “buy” rating in a research note on Monday, November 24th. Finally, BTIG Research restated a “buy” rating and set a $192.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, January 29th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $158.69.

Insider Transactions at Palvella Therapeutics

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 20.50% of the company’s stock.

Palvella Therapeutics Price Performance

Shares of Palvella Therapeutics stock opened at $85.66 on Friday. Palvella Therapeutics, Inc. has a one year low of $18.05 and a one year high of $114.69. The stock’s 50-day moving average is $91.60 and its 200 day moving average is $77.06. The firm has a market cap of $1.01 billion, a price-to-earnings ratio of -32.57 and a beta of -0.16.

Palvella Therapeutics Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.